EUVIMEDEUVIMED entdecken
Open Access

Glucocorticoid Receptors Drive Breast Cancer Cell Migration and Metabolic Reprogramming via PDK4

Amy R Dwyer iD, Carlos Perez Kerkvliet, Thu H Truong, Kyla M Hagen, Raisa I Krutilina, Deanna N Parke, Robert H Oakley, Christopher Liddle, John A Cidlowski, Tiffany N Seagroves, Carol A Lange iD

Endocrinology · 06.06.2023 · 164 (7)

DOI: 10.1210/endocr/bqad083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, online erschienen am 24.05.2023. Verfasst von Amy R Dwyer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA. Hauptthemen laut MEDLINE: Receptors, Glucocorticoid, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Corticosteroids act on the glucocorticoid receptor (GR; NR3C1) to resolve inflammation and are routinely prescribed to breast cancer patients undergoing chemotherapy treatment to alleviate side effects. Triple-negative breast cancers (TNBCs) account for 15% to 20% of diagnoses and lack expression of estrogen and progesterone receptors as well as amplified HER2, but they often express high GR levels. GR is a mediator of TNBC progression to advanced metastatic disease; however, the mechanisms underpinning this transition to more aggressive behavior remain elusive. We previously showed that tissue/cellular stress (hypoxia, chemotherapies) as well as factors in the tumor microenvironment (transforming growth factor β [TGF-β], hepatocyte growth factor [HGF]) activate p38 mitogen-activated protein kinase (MAPK), which phosphorylates GR on Ser134. In the absence of ligand, pSer134-GR further upregulates genes important for responses to cellular stress, including key components of the p38 MAPK pathway. Herein, we show that pSer134-GR is required for TNBC metastatic colonization to the lungs of female mice. To understand the mechanisms of pSer134-GR action in the presence of GR agonists, we examined glucocorticoid-driven transcriptomes in CRISPR knock-in models of TNBC cells expressing wild-type or phospho-mutant (S134A) GR. We identified dexamethasone- and pSer134-GR-dependent regulation of specific gene sets controlling TNBC migration (NEDD9, CSF1, RUNX3) and metabolic adaptation (PDK4, PGK1, PFKFB4). TNBC cells harboring S134A-GR displayed metabolic reprogramming that was phenocopied by pyruvate dehydrogenase kinase 4 (PDK4) knockdown. PDK4 knockdown or chemical inhibition also blocked cancer cell migration. Our results reveal a convergence of GR agonists (ie, host stress) with cellular stress signaling whereby pSer134-GR critically regulates TNBC metabolism, an exploitable target for the treatment of this deadly disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, GlucocorticoidTriple Negative Breast NeoplasmsAnimalsFemaleHumansMiceAdaptor Proteins, Signal TransducingCell Line, TumorCell MovementPhosphofructokinase-2Tumor MicroenvironmentProtein KinasesPyruvate Dehydrogenase Acetyl-Transferring Kinase

Stichwörter der Autor:innen

breast cancerglucocorticoid receptormetabolic adaptationmetastasismigrationphosphorylation

Substanzen

Adaptor Proteins, Signal TransducingPhosphofructokinase-2Receptors, GlucocorticoidNEDD9 protein, humanPFKFB4 protein, humanpyruvate dehydrogenase kinase 4Protein KinasesPDK4 protein, humanPyruvate Dehydrogenase Acetyl-Transferring KinasePdk4 protein, mouse

Autor:innen und Institutionen

  • Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.
  • Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, SA 5005, Australia.
  • Department of Pathology and Laboratory Medicine and Center for Cancer Research, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
  • Signal Transduction Laboratory, Department of Health and Human Services, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 27709, USA.
  • Storr Liver Centre, The Westmead Institute for Medical Research and University of Sydney School of Medicine, Darlington, NSW, 2006, Australia.
  • Departments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology, University of Minnesota, Minneapolis, MN, 55455, USA.

ORCID-Profile: Amy R Dwyer, Carol A Lange

Förderung

  • Intramural NIH HHS
  • NCI NIH HHS
  • NCATS NIH HHS
  • NIEHS NIH HHS
  • National Institutes of Health's
  • National Center for Advancing Translational Sciences
  • Intramural Research Program
  • NIEHS

Zitieren

APA

Dwyer, A. R., Perez Kerkvliet, C., Truong, T. H., Hagen, K. M., Krutilina, R. I., Parke, D. N., Oakley, R. H., Liddle, C., Cidlowski, J. A., Seagroves, T. N., & Lange, C. A. (2023). Glucocorticoid Receptors Drive Breast Cancer Cell Migration and Metabolic Reprogramming via PDK4. Endocrinology, 164(7). https://doi.org/10.1210/endocr/bqad083

Vancouver

Dwyer AR, Perez Kerkvliet C, Truong TH, Hagen KM, Krutilina RI, Parke DN, et al. Glucocorticoid Receptors Drive Breast Cancer Cell Migration and Metabolic Reprogramming via PDK4. Endocrinology. 2023;164(7). doi:10.1210/endocr/bqad083

BibTeX
@article{Dwyer2023,
  author = {Dwyer, Amy R and Perez Kerkvliet, Carlos and Truong, Thu H and Hagen, Kyla M and Krutilina, Raisa I and Parke, Deanna N and Oakley, Robert H and Liddle, Christopher and Cidlowski, John A and Seagroves, Tiffany N and Lange, Carol A},
  title = {Glucocorticoid Receptors Drive Breast Cancer Cell Migration and Metabolic Reprogramming via PDK4},
  journal = {Endocrinology},
  year = {2023},
  volume = {164},
  number = {7},
  doi = {10.1210/endocr/bqad083}
}
Kostenlos starten →